Latest / Tel Aviv Diary Podcast
The Fight to Beat ALS: Alon Ben-Noon on PrimeC, Persistence, and Israeli Biotech
In this episode of Tel Aviv Diary, Marc speaks with Alon Ben-Noon, founder and CEO of NeuroSense Therapeutics (Nasdaq: NRSN), about Israel’s bid to change the prognosis for ALS. Ben-Noon traces his path from early years in Nahariya, studies in industrial engineering and an MBA, and work at Perrigo and Teva, to launching his own consultancy and eventually founding NeuroSense. He recounts how meeting ALS patient and activist Shai Rishoni pushed him from advising biotech companies to building one, and how that encounter led to the development of PrimeC, a combination drug designed to target key…
The skinny
The skinny isn't ready yet — notes appear once the transcript is processed.